iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-007, an antisense inhibitor that is in Phase II clinical trial for the treatment of diabetic macular edema; and iCo-008 (Bertilimumab), a human immunoglobulin monoclonal antibody, which is in Phase I clinical trial to treat sight threatening ocular allergies and various systemic indications. The company also develops Oral Amphotericin B Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections in immune-compromised patients, such as in HIV/AIDS, cancer, transplant recipients, diabetics, etc., as well as certain parasitical infections. iCo Therapeutics Inc. has partnership arrangements with Isis Pharmaceuticals, Inc.; MedImmune Limited; Immune Pharmaceuticals Inc.; AstraZeneca; and the University of British Columbia. iCo Therapeutics Inc. was founded in 2005 and is headquartered in Vancouver, Canada.
ico therapeutics inc (ICOTF:OTC US)
760-777 Hornby Street
Vancouver, BC V6Z 1S4
|No competitor information is available for ICOTF.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact ICO THERAPEUTICS INC, please visit www.icotherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.